An Evaluation of the High Frequency Digit Triplet Test as a Screening Tool for Early Detection of Hearing Loss in Individuals With Cystic Fibrosis
试验速览
- 阶段
- 不适用
- 入组人数
- 388
- 试验地点
- 3
- 主要终点
- Proportion of patients in whom the HFDT test accurately predicts the presence of absence of hearing loss.
研究概览
简要总结
The purpose of this study is to find out whether the High Frequency Digit Triplet test can be used to screen patients with cystic fibrosis for hearing loss in conditions of health and pulmonary exacerbation. It is also designed to find out the youngest age at which a child can perform the test, the prevalence of hearing loss in a CF population and the prevalence of genetic mutations known to be associated with hearing loss in the same population.
详细描述
Patients will be identified from the clinic list of four Cystic Fibrosis centres (Nottingham University Hospitals NHS (National Health Service) Trust, adults and children, West Midlands Adult Cystic Fibrosis Centre and Birmingham Children's Hospital).
In the first work stream patients 11 years old and over will answer some hearing screening questions and an ear examination and tympanogram. They will then have the new test (the High Frequency Digit Triplet, HFDT, test), the standard tests (Pure tone audiogram (PTA) including high frequencies, Distortion Product Otoacoustic Emissions) and then repeat the new test to look for order effect. These will be compared to validate the HFDT as a screening tool for hearing loss.
In the second work stream the investigators are looking to see if the test is feasible when a patient is unwell and about to start a course of IV antibiotics. The patients will have the same tests as in work stream 1 (though the high-frequency PTA may be modified if they are too unwell to complete it). They will then have the tests repeated at the next clinic visit (approximately 6-8 weeks later).
In the third work stream children aged 5-10 years will have the same tests. This is to discover the youngest age at which the HFDT test can reliably be performed. To ensure that the CF condition does not itself affect the ability to perform the test the investigators will compare CF children to healthy control children the same age.
The investigators will take blood and saliva samples from CF patients to look for mutations in mitochondrial genes which are known to be associated with aminoglycoside induced hearing loss.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Screening
- 盲法
- None
入排标准
- 年龄范围
- 5 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Work stream 1
- •A diagnosis of CF, confirmed by genotype or sweat test, with characteristic clinical features.
- •Aged 11 years and over.
- •Informed consent. For age 11 to 18 years, consent will be sought from both the parent and young person (provided the young person is competent).
- •Work stream 2
- •As above but the participant has a pulmonary exacerbation (as defined by Fuch's criteria) requiring intravenous antibiotics.
- •Work stream 3
- •As for work stream 1, defined above.
- •CF patients aged 5-10 years
- •Healthy control children aged 5-10 years.
- •Informed consent from parent with assent from the child.
- •Genetic Testing
- •Informed consent
- •Diagnosis of CF as above
排除标准
- •None. In individuals with a hearing aid, we will perform PTA and HFDT tests without the aid.
- •Individuals found to have conductive deafness after randomisation will be fully assessed for this prior to continuing with the study.
研究组 & 干预措施
Well patients aged 11 and over
Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
干预措施: HFDT test (Other)
Well patients aged 11 and over
Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
干预措施: Pure tone Audiogram (Other)
Acute exacerbation aged 11 and over
Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity at the beginning of a course of IV antibiotics and at their convalescent clinic visit.
干预措施: HFDT test (Other)
Acute exacerbation aged 11 and over
Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity at the beginning of a course of IV antibiotics and at their convalescent clinic visit.
干预措施: Pure tone Audiogram (Other)
Children with CF aged 5-10 years
Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
干预措施: HFDT test (Other)
Children with CF aged 5-10 years
Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
干预措施: Pure tone Audiogram (Other)
Healthy Control Children age 5-10 years.
Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
干预措施: HFDT test (Other)
Healthy Control Children age 5-10 years.
Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
干预措施: Pure tone Audiogram (Other)
结局指标
主要结局
Proportion of patients in whom the HFDT test accurately predicts the presence of absence of hearing loss.
时间窗: 2 years
This will be done in patients when they are clinically stable and at the beginning and end of a pulmonary exacerbation by comparing the HFDT test with the current gold standard test.
The youngest age at which 80% of children are able to perform the HFDT test.
时间窗: 2 years
This will be done in children aged 5-10 years and the
次要结局
- The prevalence of hearing loss in a CF population.(2 years)
- The prevalence of genetic mutations that are associated with hearing loss in a CF population.(2 years)